Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 763 across all filing types
Latest filing 2020-07-08 Major Shareholding Noti…
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development säljer del av innehavet i portföljbolaget Aprea Therapeutics och erhåller netto 39 miljoner SEK
Major Shareholding Notification Classification · 99% confidence The document announces that Karolinska Development AB has sold a portion of its holding in a portfolio company, Aprea Therapeutics, for a specific cash amount (39 million SEK). This transaction involves the disposal of shares and a change in the ownership stake. This type of corporate action, specifically related to the sale or repurchase of shares, falls under the 'Transaction in Own Shares' (POS) category if it were the company buying back its own stock, or more generally under financing/capital structure changes. However, the sale of an *investment* holding in another company is typically classified as a divestment or capital transaction. Given the provided definitions, the closest fit for an announcement detailing the sale/disposal of an investment holding, which affects the company's asset base and capital structure, is 'Capital/Financing Update' (CAP) or potentially 'Transaction in Own Shares' (POS) if interpreted broadly as a capital movement, though POS usually refers to treasury stock. Since this is a sale of an *investment* in another entity, and not a direct share buyback/issue of its own stock, 'CAP' is a strong candidate for significant capital movements. However, looking closely at the definitions, the document is a press release announcing a specific transaction involving the disposal of assets (shares in another company). This is a significant corporate event announcement. Since there is no specific category for 'Investment Sale', we must choose the best fit. 'CAP' covers fundraising/financing activities. 'POS' covers the company buying back/selling *its own* shares. Since this is a sale of an *investment*, and it is a material announcement, it is often grouped with capital structure changes. Given the options, and recognizing this is a material corporate action announcement, if it doesn't fit 'CAP' (which often implies raising new capital), it might default to a general announcement. Let's re-evaluate: The transaction results in cash inflow and changes the composition of assets. This is a capital transaction. 'CAP' (Capital/Financing Update) is the most appropriate category for significant changes in the company's capital structure or major asset disposals/acquisitions that impact its financial standing, even if it's not issuing new debt or equity directly to the public. The document is short and is an announcement, not a full report, but it is a specific type of announcement. I will classify it as CAP as it details a significant capital movement/divestment.
2020-07-08 Swedish
Karolinska Development makes a partial sale of its holdings in the portfolio company Aprea Therapeutics and receives a net of SEK 39 million
Share Issue/Capital Change Classification · 95% confidence The document announces a specific corporate action: Karolinska Development sold a partial stake in its portfolio company, Aprea Therapeutics, for a net amount of SEK 39 million. This involves a change in the company's investment holdings and capital structure related to an asset. This type of announcement, detailing a transaction involving the sale or purchase of shares/assets, fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Since it is a specific transaction affecting capital/investment portfolio value, CAP is more precise than RNS. It is not an earnings release (ER), a management change (MANG), or a director's dealing (DIRS). Given the nature of the transaction (sale of investment holdings), 'Capital/Financing Update' (CAP) is the most appropriate classification.
2020-07-08 English
Karolinska Development’s Annual General Meeting 2020
AGM Information Classification · 100% confidence The document explicitly states it contains the resolutions passed at the 'Annual General Meeting of Karolinska Development AB (publ) held June 15, 2020.' It details votes on profit appropriation, discharge from liability, election of directors and auditors, and various board proposals. This content is characteristic of the official minutes or summary of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document is comprehensive and not merely an announcement of the meeting, thus ruling out RPA or RNS.
2020-06-15 English
Karolinska Developments årsstämma 2020
AGM Information Classification · 99% confidence The document text is titled "Karolinska Developments årsstämma 2020" (Karolinska Development's Annual General Meeting 2020) and details the resolutions passed by the shareholders on June 15, 2020. Key decisions mentioned include the approval of financial statements, discharge of the board, election/re-election of board members and auditors, setting remuneration, and voting on proposals regarding share authorizations and changes to the articles of association. These are all standard items discussed and voted upon during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document is a summary of the meeting outcomes, not just an announcement of a future meeting or a proxy statement.
2020-06-15 Swedish
Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva kompletterande resultat från en fas 2a-studie av golexanolon
Earnings Release Classification · 95% confidence The document is a press release from Karolinska Development AB announcing positive supplementary results from a Phase 2a clinical trial for a drug candidate (golexanolon) developed by its portfolio company, Umecrine Cognition. It details specific statistical findings (p-values, EEG analysis, ESS scores) related to efficacy in treating extreme daytime sleepiness associated with hepatic encephalopathy. This content is characteristic of an initial announcement of periodic financial/clinical results, focusing on key highlights rather than a comprehensive report or a transcript. The final paragraph explicitly states that more detailed information will be published separately by Umecrine Cognition, suggesting this document serves as the primary, high-level disclosure. This aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical results (even if clinical/operational rather than purely financial in this context, it serves the same disclosure function for investors), or potentially a Regulatory Filing (RNS) if ER is too narrow. Given the focus on presenting key results immediately after analysis, ER is the most specific fit among the options for a results announcement. FY 2020
2020-05-08 Swedish
Karolinska Development’s portfolio company Umecrine Cognition presents positive additional results from a phase 2a study of golexanolone
Regulatory Filings Classification · 90% confidence The document is a press release dated May 8, 2020, announcing positive supplementary results from a Phase 2a study of a drug candidate (golexanolone) by a portfolio company (Umecrine Cognition). It details clinical findings (EEG analysis, ESS scores) and mentions that Umecrine Cognition will revisit its development strategy. The final paragraph explicitly states: "Further information about golexanolone and the updated results of the phase 2a study will be issued by Umecrine Cognition in a separate press release...". The document itself is an announcement of clinical data and strategic updates, not the comprehensive financial report (10-K, IR) or the subsequent detailed presentation (IP). Since it is an announcement regarding clinical/business updates that doesn't fit perfectly into ER (Earnings Release) or LTR (Legal Proceedings), and it is a formal communication, it most closely aligns with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but given the format and content being a news update, RNS is the most appropriate general category for non-standard, material announcements not covered by other specific codes. However, because it is a detailed update on clinical trial results and strategic direction, it functions similarly to an Investor Presentation (IP) or a specialized business update. Given the options, and recognizing this is a material business update about drug development progress, it is a significant announcement. Since it is not a standard earnings release (ER) or a formal legal filing, and it is not explicitly an announcement *of* a report (RPA), it falls best under the general Regulatory Filings (RNS) category as a material corporate event disclosure, or potentially an Investor Presentation (IP) if the intent is to convey detailed findings to investors. Given the context of clinical trial results being presented, IP is a strong candidate, but RNS is the safest fallback for material news not fitting other specific categories. I will classify it as RNS as it is a general regulatory announcement of material news.
2020-05-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.